Bicara Therapeutics Common Stock Total Current Liabilities

Bicara Therapeutics Common Stock (BCAX) currently reports a total current liabilities of $39M as of March 2026. That compares with $19M in the prior-year period — up 105.8% year over year. Use the charts on this page to explore Bicara Therapeutics Common Stock's total current liabilities history and peer comparisons.

Bicara Therapeutics Common Stock's total current liabilities increased from $19M to $39M — a 105.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bicara Therapeutics Common Stock reported $39M in total current liabilities as of March 2026. That compares with $19M in the prior-year period — up 105.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $39M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bicara Therapeutics Common Stock, and consider following BCAX for alerts when major investors trade the stock.

Bicara Therapeutics Common Stock is classified in the Healthcare sector. On total current liabilities, it currently shows $39M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BCAX with unrelated industries.